Skip to main content

Table 1 Patient characteristics

From: Characteristics and outcomes analysis of ovarian Sertoli–Leydig cell tumors (SLCTs): analysis of 15 patients

No

Age

Clinical manifestation

Parturition

Laboratory

Ultrasound

Histopathology

Treatment

Relapse

Follow-up

Side

D (cm)

Diagnosis

Stage

Surgery

Chemotherapy

Period

Status

1

26

Amenorrhea

NO

Testosterone↑

AFP ↑

CS

R

8.5

Moderately differentiated

Ia

USO

No

93

DFS + P

2

39

Amenorrhea

voice raucity

Yes

Testosterone↑

CS

L

3

Poorly differentiated + R

Ia

USO

NVB×6

No

112

DFS

3

60

Pelvic mass

Yes

Normal

S

L

10

Moderately differentiated

Ia

BSO

no

102

DFS

4

28

Pelvic mass

No

CA125 ↑

AFP ↑

CS

L

7

Poorly differentiated +R

Ic

CYS + USO

BEP×4

No

64

DFS

5

60

Postmenopausal bleeding

Yes

CA199 ↑

CS

L

2

Moderately differentiated

+atypical

Ia

THBSO

No

85

DFS

6

25

Menstrual irregularity

No

Testosterone ↑

AFP ↑

C

L

4

Moderately differentiated + R

Ia

USO

BEP×4

NO

66

DFS + P

7

61

Abdominal pain

Yes

Normal

CS

R

4

Moderately differentiated

Ia

THBSO

No

36

DFS

8

48

Abdominal pain

Yes

Normal

CS

R

9

Poorly differentiated

Ia

THBSO+S

BEP×6

No

43

DFS

9

44

Pelvic mass

Yes

Normal

S

R

7.5

Moderately differentiated

Ia

THBSO+S

No

49

DFS

10

69

Abdominal pain

Yes

Normal

S

R

5

Moderately differentiated

Ia

THBSO

No

20

DFS

11

58

Pelvic mass

Yes

Normal

C

R

10

Moderately differentiated

Ia

THBSO

NO

28

DFS

12

65

Postmenopausal bleeding

Yes

CA125↑ CEA↑ AFP↑ CA199↑

R

0.5

Poorly differentiated +EC + R

Ia

THBSO+S

TC×6

No

68

DFS

13

26

Amenorrhea

No

Normal

C

L

2.5

Moderately differentiated + R

Ic

USO

BEP×4

YES

87

AWD

14

27

Menstrual irregularity

No

Testosterone↑

AFP

C

L

4

Moderately differentiated + R

Ia

USO

BEP×4

NO

32

DFS + P

15

28

Menstrual irregularity

Yes

Normal

CS

L

6

Moderately differentiated + R

Ia

USO

BEP×4

No

86

DFS

  1. CS cyst and solid, C cyst, S solid, R right, L left, EC endometrial cancer, USO unilateral salpingo-oophorectomy, BSO bilateral salpingo-oophorectomy, CYS cystectomy, THBSO total hysterectomy and bilateral salpingo-oophorectomy, S(treatment) staging surgery (omentectomy ± pelvic lymphadenectomy), BEP (bleomycin + etoposide + cisplatin), NVB (nedaplatin + vincristine + bleomycin), TC (paclitaxel + carboplatin), DFS disease-free survival, DFS + P disease-free survival and pregnancy, AWD alive without disease after relapse treatment